

DAFTAR PUSTAKA

- Abdallah, T. M., Elmardi, K.A., Elhassan, A.H., Omer, M.B., Elhag, M.S., Desogi, M.A. 2014. Comparison of artesunate and quinine in the treatment of severe *P. falciparum* malaria at Kassala hospital, Sudan. *Journal of Infection in Developing Countries*, 8(5), pp. 611–615. doi: 10.3855/jidc.3813.
- Achan, J., Talisuna, A.O., Erhart, A., Yeka, A., Tibenderana, J.K., *et al.* 2011. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. *Malaria Journal*. 10:144.
- Akhwale, W. S., Luma, J.K., Kanekoa, A., Etoa, H., Obonyod, C., Björkman, A., Kobayakawa, T. 2004. Anemia and malaria at different altitudes in the western highlands of Kenya. *Acta Tropica*, 91(2), pp. 167–175. doi: 10.1016/j.actatropica.2004.02.010.
- Almeida, E.D. & Vieira, J.L.F. 2016. Factors associated with non-adherence to the treatment of vivax malaria in a rural community from the Brazilian Amazon Basin. *Revista da Sociedade Brasileira de Medicina Tropical*. 49(2):248-251, doi: 10.1590/0037-8682-0275-2015.
- Alexandre, M. A. A., Benzecry, S.G., Siqueira, A.M., Vitor-Silva, S., Melo, G.C., Monteiro, W.M., *et al.* 2015. The Association between Nutritional Status and Malaria in Children from a Rural Community in the Amazonian Region: A Longitudinal Study. *PLoS Neglected Tropical Diseases*, 9(4), pp. 1–15. doi: 10.1371/journal.pntd.0003743.
- Antony, H. A., & Parija, S. C. 2016. Antimalarial drug resistance: An overview. *Tropical Parasitology*, 6(1), 30–41. <http://doi.org/10.4103/2229-5070.175081>.
- Arama, C., Maiga, B., Dolo, A., Kouriba, B., Traore, B., Crompton, P.D., *et al.* 2015. Ethnic differences in susceptibility to malaria: What have we learned from immuno-epidemiological studies in West Africa?. *Acta Tropica*. Elsevier B.V., 146, pp. 152–156. doi: 10.1016/j.actatropica.2015.03.023.
- Arama, C., Diarra I., Kouriba B., Sirois F., Fedoryak O., Thera M.A., Coulibaly D., Lyke K.E., Plowe C.V., Chretien., Doumbo O.K., Mbikay M. .2018. Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. *PLoS ONE*. 13(2), pp. 1–10. doi: 10.1371/journal.pone.0192850.
- Ashley, E. A., Pyae Phy, A. and Woodrow, C. J. 2018. Malaria : *The Lancet*. doi: 10.1016/S0140-6736(18)30324-6.
- Autino B., Noris A., Russo R., & Castelli F. 2012. Epidemiology of malaria in endemic areas. *Mediterranean Journal of Hematology and Infectious Diseases*, 4(1). doi:

10.4084/MJHID.2012.060.

Badan Perencanaan dan Pembangunan Daerah. 2014. Rencana Pembangunan Jangka Menengah Daerah 2014-2019. Kabupaten Mimika : Papua.

Bannister, L. H. & Sherman, I. W. 2009. *P. : Encyclopedia of Life Sciences*. doi: 10.1002/9780470015902.a0001970.pub2.

Batty, K.T., Thu, L.T.A., Davis, T.M.E., Ilet, K.F., Mai, T.X., *et al.* 1998. A Pharmacokinetic and Pharmacodynamic Study of Intravenous versus Oral Artesunate in Uncomplicated *Falciparum* Malaria. *Br J Clin Pharmacol*. 45: 123 - 129.

Barcus, M.J., Basri, H., Picarima, H., Manyakori, C., Sekartuti, Elyazar, I., *et al.* 2018. Demographic Risk Factors for Severe and Fatal Vivax and *Falciparum* Malaria Among Hospital Admissions in Northeastern Indonesian Papua. *The American Journal of Tropical Medicine and Hygiene*, 77(5), pp. 984–991. doi: 10.4269/ajtmh.2007.77.984.

Bloand, P. B. 2001. *WHO/CDS/CSR/DRS/2001.4 Drug resistance in malaria Drug resistance in malaria*. Available at: <http://www.who.int/emc>.

Byakika-Kibwika, P., Ndeezi, G., & Kamya, M. R. 2009. Health care related factors associated with severe malaria in children in Kampala, Uganda. *African health sciences*. 9(3), pp. 206–10. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2887032&tool=pmcentrez&rendertype=abstract>.

Center For Infectious Disease Research and Policy. 2018. Drug-resistant malaria spreading fast in Southeast Asia. Available at cidrap.umn.edu/news-perspective/2018/02/drug-resistant-malaria-spreading-fast-southeast-asia.

Cotter, C., Sturrock, H.J.W., Hsiang, M.S., Liu, J., Phillips, A.A., Hwang, J., Gueye, C.S., Fullman, N., Gosling, R.D., Feachem, R.G.A. 2013. The changing epidemiology of malaria elimination: New strategies for new challenges. *The Lancet*. doi: 10.1016/S0140-6736(13)60310-4.

Cucunubá, Z. M., Guerra, A.P., Rahirant, S.J., Rivera, J.A., Cortés, L.J., Nicholls, R.S. 2008. Asymptomatic *P. spp.* infection in Tierralta, Colombia. *Memorias do Instituto Oswaldo Cruz*, 103(7), pp. 668–673. doi: 10.1590/S0074-02762008000700007.

Cui, L., Mharakurwa, S., Ndiaye, D., Rathod, P.K., Rosenthal, P.J. 2015. Antimalarial drug resistance: Literature review and activities and findings of the ICEMR network. *American Journal of Tropical Medicine and Hygiene*. doi: 10.4269/ajtmh.15-0007.

- Daher, A., Silva, J.C.A.L., Stevens, A., Marchesini, P., Fontes, C.J., Ter Kuile, F.O., Lalloo, D.G. 2019. Evaluation of *P. vivax* malaria recurrence in Brazil. *Malaria Journal*. BioMed Central, 18(1), pp. 1–10. doi: 10.1186/s12936-019-2644-y.
- Dama, S., Niangaly, H., Djimde, M., Sagara, I., Guindo, C.O., Zeguime, A., Dara, A., *et al.* 2018. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated *P. falciparum* malaria in Mali. *Malaria Journal*. BioMed Central, 17(1), pp. 4–11. doi: 10.1186/s12936-018-2496-x.
- Davlanges, E., Dimbu, P.R., Ferreira, C.M., Joao, M.F., Pode, D., Felix, J., *et al.* 2018. Efficacy and safety of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for the treatment of uncomplicated *P. falciparum* malaria in three provinces in Angola, 2017. *Malaria Journal*. BioMed Central, 17 (144). doi: 10.1186/s12936-018-2290-9.
- Dolo, A., Maiga B., Tolo, Y., Tapily, A., Arama, C., Daou, M., Baby, M., Traore, B., Doumbo, O. 2012. Relation entre l’anémie et le paludisme dans deux groupes ethniques vivant en sympatrie au Mali. *Bulletin de la Societe de Pathologie Exotique*, 105(5), pp. 370–376. doi: 10.1007/s13149-012-0265-6.
- Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyto, A.P., *et al.* 2005. Pathophysiology , clinical presentation and treatment of cerebral malaria. *Neurology Asia* : 10. pp. 67–77. Available at: http://www.neurology-asia.org/articles/20052_067.pdf.
- Doolan, D. L., Dobaño, C. and Baird, J. K. 2009. Acquired immunity to Malaria. *Clinical Microbiology Reviews*, 22(1), pp. 13–36. doi: 10.1128/CMR.00025-08.
- Douglas, N.M., Nosten, F.X., Ashley, E.A., Phaiphun, L., Vugt, M., Singhasivanon, P., White, N.J., Pric, R.N. 2011. *P. vivax* Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics. *Clinical Infectious Diseases*. 52(5):612–620.
- Douglas, N. M., Lampah, D.A., Kenangalem, E., Simpson, J.A., Poespoprodjo, J.R., Sugiarto P., *et al.* 2013. Major Burden of Severe Anemia from Non-Falciparum Malaria Species in Southern Papua: A Hospital-Based Surveillance Study. *PLoS Medicine*, 10(12), pp. 1–17. doi: 10.1371/journal.pmed.1001575.
- Dinas Kesehatan. 2012. Profil Kesehatan Kabupaten Mimika 2012. Mimika : Papua
- Drakeley, C.J., Carneiro, I., Reyburn, H., Malima, R., Lusingu, J.P.A., Cox, J., *et al.* 2005. Altitude-Dependent and -Independent Variations in *P. falciparum* Prevalence in Northeastern Tanzania. *The Journal of Infectious Diseases*, 191(10), pp. 1589–1598. doi: 10.1086/429669.
- Duffy, P.E. & Fried, M. 2006. Red blood cells that do and red blood cells that don’t:

how to resist a persistent parasite. *TRENDS in Parasitology*, Vol.22, No.3.

- Eder, M., Farne, H., Cargill, T., Abbara, A., Davidson, R.N. 2012. Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre. *Pathogens and Global Health*, 106(3), pp. 181–187. doi: 10.1179/2047773212Y.0000000032.
- Ellman, R., Maxwell, C., Finch, R., Sayo, D., *et al.* 1998. Malaria and anaemia at different altitudes in the Muheza district of Tanzania: Childhood morbidity in relation to level of exposure to infection. *Annals of Tropical Medicine and Parasitology*, 92(7), pp. 741–753. doi: 10.1080/00034983.1998.11813336.
- Elyazar, I.R.F., Hay, S.I., Baird, J.K. 2011. Malaria Distribution, Prevalence, Drug Resistance and Control in Indonesia. *Adv Parasitol.* doi: 10.1016/B978-0-12-385897-9.00002-1.
- Fanello, C., Onyamboko, M., Lee, S.J., Woodrow, C., Setaphan, S., Chotivanich, K., *et al.* 2017 . Post-treatment haemolysis in African children with hyperparasitaemic falciparum malaria; a randomized comparison of artesunate and quinine. *BMC Infectious Diseases*. BMC Infectious Diseases, 17(1), pp. 1–8. doi: 10.1186/s12879-017-2678-0.
- Färnert, A., Wys, K., Dasheti, S., Naucner, P. 2015. Duration of residency in a non-endemic area and risk of severe malaria in African immigrants. *Clinical Microbiology and Infection*. Elsevier Ltd, 21(5), pp. 494–501. doi: 10.1016/j.cmi.2014.12.011.
- Fevang, P. Havemann, K., Fevang, B., & Høstmark, A.T. 2018. Malaria and Malnutrition : Kwashiorkor Associated with Low Levels of Parasitaemia. 2018.
- Fontecha, G.A., Mendoza, M., Banegas, E., Poorak, M., De Oliveira, A.M. 2012. Comparison of molecular tests for the diagnosis of malaria in Honduras. National Autonomous University of Honduras. Microbiology School: Honduras.
- Gachot, B., & Ringwald, P. 1998. Severe malaria. *Revue du Praticien*, 48(5), pp. 273–278. doi: 10.1111/tmi.12313.
- Genton, B., Acremont, V.D., Rare, L., Baea, K., Reeder, J.C., Alpers, M.P., Müller, I. 2008. P. vivax and Mixed Infections Are Associated with Severe Malaria in Children: A Prospective Cohort Study from Papua New Guinea. *PLoS Medicine*, 5(6), p. e127. doi: 10.1371/journal.pmed.0050127.
- Giao, P.T. & Vries, P.J. 2001. Pharmacokinetic interaction of antimalarial agent. *Clin Pharmacokinetic Journal*. 40(5), 343-373.
- Goheen, M. M. Wegmuller, R., Bah, A., Darboe, B., Danso, E., Affara, M., *et al.* 2016. Anemia Offers Stronger Protection Than Sick Cell Trait Against the

- Erythrocytic Stage of Falciparum Malaria and This Protection Is Reversed by Iron Supplementation. *EBioMedicine*. Elsevier B.V., 14, pp. 123–130. doi: 10.1016/j.ebiom.2016.11.011.
- Haldar, K. & Mohandas, M. 2010. NIH Public Access: Malaria, erythrocytic infection, and anemia. *Hematology*, (574). doi: 10.1182/asheducation-2009.1.87.Malaria.
- Hansen, V., Oren, E., Dennis, L.K., Brown, H.E. 2016. Infectious Disease Mortality Trends in the United States, 1980-2014. *Jama*, 316(20), p. 2149. doi: 10.1001/jama.2016.12423.
- Hasugian, A.R., Purba, H.L.E., Kenangalem, E., Wuwung, R.M., Ebsworth, E.P., Maristela, R., *et al.* 2008. Dihydroartemisinin-Piperaquine versus Artesunate-Amodiaquine: Superior Efficacy and Posttreatment Prophylaxis against Multidrug-Resistant *P. falciparum* and', 44(8), pp. 1067–1074. doi: 10.1086/512677.Dihydroartemisinin-Piperaquine.
- Haque, U., Magalhães, R.J.S., Mitra, D., Kolivras, K.N., Schmidt, W.F., Haque, R., & Glass, G.E. 2011. The role of age, ethnicity and environmental factors in modulating malaria risk in Rajasthali, Bangladesh. *Malaria Journal*. BioMed Central Ltd, 10(1), p. 367. doi: 10.1186/1475-2875-10-367.
- Kai, O. K. and Roberts, D. J. 2008. The pathophysiology of malarial anaemia: Where have all the red cells gone?. *BMC Medicine*, 6, pp. 4–7. doi: 10.1186/1741-7015-6-24.
- Kamus Besar Bahasa Indonesia. 20012.
- Kazembe, L. N., Kleinschmidt, I. and Sharp, B. L. 2006. Patterns of malaria-related hospital admissions and mortality among Malawian children: An example of spatial modelling of hospital register data. *Malaria Journal*, 5, pp. 1–10. doi: 10.1186/1475-2875-5-93.
- Karyana, M., Burdarm, L., Yeung, S., Kenangalem, E., Wariker N., *et al.* 2008. Malaria morbidity in Papua Indonesia, an area with multidrug resistant *P. vivax* and *P. falciparum*. *Malaria Journal*. doi: 10.1186/1475-2875-7-148.
- Keene, C.M., Dondorp, A., Crawley, J., Ohuma, E.O., Mukaka, M. (2018). A Competing-Risk Approach for Modeling Length of Stay in Severe Malaria Patients in South-East Asia and the Implications for Planning of Hospital Services. *Clinical Infectious Diseases*, 67(7), pp. 1053–1062. doi: 10.1093/cid/ciy211.
- Kelly-Hope, L.A., Hemingway, J., McKenzie, F.E. 2009. Environmental Factors Associated With Malaria Vectors *Anopheles gambiae* & *Anopheles funestus* in Kenya. *Malaria Journal*. doi: 10.1186/1475 - 2875 - 8 - 268.

- Kementerian Kesehatan Republik Indonesia. 2012. Buku Saku Penatalaksanaan Kasus Malaria. Ditjen Pengendalian Penyakit dan Penyehatan Lingkungan : KEMENKES RI. 614.532.ind.m
- Kementerian Kesehatan Republik Indonesia. 2018. Hari Malaria Sedunia, Pemerintah Perluas Wilayah Bebas Malaria. Biro Komunikasi dan Pelayanan Masyarakat: KEMENKES RI
- Kenangalem, E., Karyana, M., Burdarm, L., Yeung, S., Simpson, J.A., Tjitra, E., *et al.* 2016. *P. vivax* infection: A major determinant of severe anaemia in infancy. *Malaria Journal*. BioMed Central, 15(1), pp. 1–10. doi: 10.1186/s12936-016-1373-8.
- Kipanga, P.N., Omondi, D., Mireji, P.O., Sawa, P., Masiga, D.K., Villinger, J. High resolution melting analysis reveals low *Plasmodium* parasitemia infections among microscopically negative febrile patients in western Kenya. *Malaria Journal*. 13: 429.
- Kokwaro, G. (2009) ‘Ongoing challenges in the management of malaria’, *Malaria Journal*. doi: 10.1186/1475-2875-8-S1-S2.
- Kurth, F., Develoux, M., Mechain, M., Malvy, D., Clerinx, J., Antinori, S., *et al.* 2017. Severe malaria in Europe: an 8-year multi-centre observational study. *Malaria Journal*. BioMed Central, 16(1), pp. 1–11. doi: 10.1186/s12936-016-1673-z.
- Laishram, D. D., Sutton, P.L., Nanda, N., Sharma, V.L., Sobti, R.C., Carlton, J.M., Joshi, H. 2012. The complexities of malaria disease manifestations with a focus on asymptomatic malaria. *Malaria Journal*, 11, pp. 1–15. doi: 10.1186/1475-2875-11-29.
- Laochan, N., Zaloumis, S.G.G., Imwong, M., Uthai, U.L., Brockman A., Sriprawat, K., *et al.* 2015. Intervals to *P. falciparum* recurrence after anti-malarial treatment in pregnancy: A longitudinal prospective cohort. *Malaria Journal*, 14(1), pp. 1–9. doi: 10.1186/s12936-015-0745-9.
- Lin, J. T., Juliano, J. J., & Wongsrichanalai, C. 2010. Drug-resistant malaria: The era of ACT’, *Current Infectious Disease Reports*. doi: 10.1007/s11908-010-0099-y.
- Lithanatudom, P., Wipasa, J., Inti, P., Chawansuntati, K., Svasti, S., Fucharoen, S., Kangwanpong, D., Kampuansai J. 2016. Hemoglobin e prevalence among ethnic groups residing in malaria-endemic areas of Northern Thailand and its lack of association with *P. falciparum* invasion in vitro. *PLoS ONE*, 11(1), pp. 1–10. doi: 10.1371/journal.pone.0148079.
- Luzzatto, L. (2018) ‘Genes expressed in red cells could shape a malaria attack’, *The Lancet Haematology*. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license, 5(8), pp. e322–e323. doi:

10.1016/s2352-3026(18)30110-8.

- Martensson, A., Stromberg, J., Sisowath, C., Msellem, M.I., Gil, J. P., Montgomery, S.M., *et al.* 2005). Efficacy of Artesunate Plus Amodiaquine versus That of Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood P. falciparum Malaria in Zanzibar, Tanzania. *Clinical Infectious Diseases*, 41(8), pp. 1079–1086. doi: 10.1086/444460.
- Marquet, S. 2017. Overview of human genetic susceptibility to malaria: from parasitemia control to severe disease. *Infection, Genetic, and Evolution*. S1567-1348(17)30188.
- Mbanefo, E. C., Ahmed, A.M., Titouna¹, A., Elmaraezy, A., Trang, N.T.H., Long, N.P. 2017. Association of glucose-6-phosphate dehydrogenase deficiency and malaria: A systematic review and meta-analysis. *Scientific Reports*, 7(March), pp. 1–10. doi: 10.1038/srep45963.
- McCarthy, A. E., Morgan, C., Prematunge, C., Geduld, J. 2015. Severe malaria in Canada, 2001-2013. *Malaria journal*. p. 151. doi: 10.1186/s12936-015-0638-y.
- Mens, P. F., Sawa, P., Amsterdam, S.M.V., Versteeg, I., Omar, S.H., Schallig, H.DFH., Kager, P.A. 2008. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated P. falciparum malaria in western Kenya. *Malaria Journal*, 7, pp. 1–8. doi: 10.1186/1475-2875-7-237.
- Moonen, B., Cohen, J.M., Snow, R.W., Slutsker, L., Drakeley, C., Smith, D.L., Abeyasinghe, R.R., Rodriguez, M.H., Maharaj, R., Tanner, M., Targett, G. 2010. Series Malaria Elimination 3 Operational strategies to achieve and maintain malaria elimination. *The Lancet*, 376, pp. 1592–1603. doi: 10.1016/S0140-6736(13)62238-2.
- Moorthy, V. S., Newman, R. D., & Okwo-Bele, J. M. 2013. Malaria vaccine technology roadmap. *The Lancet*. doi: 10.1016/S0140-6736(13)62238-2.
- Müller, I., Genton B., Rare, L., Kiniboro, B., Kastens, L., Zimmerman, P., *et al.* 2009. Three different P. species show similar patterns of clinical tolerance of malaria infection. *Malaria Journal*, 8(1), pp. 1–11. doi: 10.1186/1475-2875-8-158.
- Murhandarwati, E.E.H., Fuad, A., Sulistyawati, Wijayanti, M.A., Bia, M.B., Widartono, B.S., Kuswanto, Lobo, N.F., Supargiyono, Hawley, W.A. 2015. Change of strategy is required for malaria elimination: a case study in Purworejo District, Central Java Province, Indonesia. *malaria journal*. 14:318. doi: 10.1186/s12936-015-0828-7.
- Nambozi, M., Kabuya, J.B., Hachizovu¹, S., Mwakazanga¹, D., Mulenga, J., Kasongo, W., Buyze, J., Mulenga, M., Geertruyden, J.V., D'Alessandro, U. 2017.

Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria. *Malaria Journal*. BioMed Central, 16(1), pp. 1–13. doi: 10.1186/s12936-017-1851-7.

Ndungu, F.M., Lundblom, K., Rono, J., Illingworth, J., Eriksson, S., Farnert, A. 2013. Long-lived *P. falciparum* specific memory B cells in naturally exposed Swedish travelers. *European Journal of Immunology*, 43(11), pp. 2919–2929. doi: 10.1002/eji.201343630.

Nguyen, H. Eede, P., Overmeir, C., Thang, N.D., Hung, L.X., Alessandro, U.D., Erhart, A. 2012. Marked age-dependent prevalence of symptomatic and patent infections and complexity of distribution of human *P. species* in central Vietnam. *American Journal of Tropical Medicine and Hygiene*, 87(6), pp. 989–995. doi: 10.4269/ajtmh.2012.12-0047.

Olliaro, P. (2008) ‘Editorial Commentary: Mortality Associated with Severe *P. falciparum* Malaria Increases with Age’, *Clinical Infectious Diseases*, 47(2), pp. 158–160. doi: 10.1086/589288.

Osarfo, J., Tagbor, H., Cairns, M., Alifrangis, M., Magnussen, P. 2017. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine for treatment of malaria infection in pregnancy in Ghana: an open-label, randomised, non-inferiority trial. *Tropical Medicine and International Health*, 22(8), pp. 1043 - 1052. doi: 10.1111/tmi.12905.

Pacheco, M. A., Perez, M.L., Vallejo, A.F., Herrera, S., Herrera, M.A., Escalante, A.A. *et al.* 2016. Multiplicity of Infection and Disease Severity in *P. vivax*. *PLoS Neglected Tropical Diseases*, 10(1), pp. 1–18. doi: 10.1371/journal.pntd.000435.

Pascual, C.C., Kai, O., Cheung, J.O.P., Williams, S., Lowe, B., Nyanoti, M., *et al.* 2006. Suppression of erythropoiesis in malarial anemia is associated with hemozoin in vitro and in vivo. *Blood*, 108(8), pp. 2569–2577. doi: 10.1182/blood-2006-05-018697.

Patel, D.N., Pradeep, P., Surti, M.M., Agarwal, S.B. 2003. *Acta chirurgica Italica*. 13(3), pp. 471–495.

Phillips, A., Bassett, P., Zeki, S., Newman, S., & Pasvol, G. 2009. Risk Factors for Severe Disease in Adults with *Falciparum* Malaria. *Clinical Infectious Diseases*, 48(7), pp. 871–878. doi: 10.1086/597258.

Plucinski, M. M., Dimbu, P.F., Macaia, A.P., Ferreira, C.M., Samutondo, C., Quivinja, J., *et al.* 2017. Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated *P. falciparum* malaria in Angola, 2015. *Malaria Journal*. BioMed Central, 16(1), pp. 1–10. doi: 10.1186/s12936-017-1712-4.

- Poespoprodjo, J. R., Kenangalem, E., Wafom, J., Chandrawati, F., Puspitasari, A.M., *et al.* 2018. Therapeutic response to dihydroartemisinin-piperaquine for *P. falciparum* and *P. Vivax* nine years after its introduction in southern Papua, Indonesia. *American Journal of Tropical Medicine and Hygiene*, 98(3), pp. 677–682. doi: 10.4269/ajtmh.17-0662.
- PrayGod, G., Frey, A., Eisenhut, M. 2008. Artemisinin derivatives and quinine in treating severe malaria in children: A systematic review. *Malaria Journal*. doi: 10.1186/1475 - 2875 - 7 - 210.
- Ramírez, J. F., Porras, B., Borrero E., & Martínez S.P. 2016. Factors associated with the severity and complication of patients with malaria hospitalized between 2009 and 2013 in three municipalities of Colombia, case control study. *Malaria Journal*. BioMed Central, 15(1), pp. 1–9. doi: 10.1186/s12936-016-1554-5.
- Rampengan, N. H., Metusala, J., Chandra, R., Salendu, P. 2014. Artesunate-amodiaquine versus artesunate-sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in children Artesunate-amodiaquine versus artesunate-sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in children. *Paediatrica Indonesiana VOLUME*, 54(1). doi: 10.14238/pi54.1.2014.46-51.
- Randall, T. D., Carragher, D. M. and Rangel-Moreno, J. 2008. Development of Secondary Lymphoid Organs. *Annual Review of Immunology*, 26(1), pp. 627–650. doi: 10.1146/annurev.immunol.26.021607.090257.
- Raposo, C.C.B.S., Santos, J.B., Santos, G.M.C., Gonçalves, E.G.R., & Silva, A.R. 2013. Plasmodium vivax malaria: related factors to severity in the State of Maranhão, Brazil. *Revista da Sociedade Brasileira de Medicina Tropical*. 46(1):67-72. doi: 10.1590/0037-868212382013.
- Ricci, F. 2012. Social Implication of Malaria and Their Relationship With Poverty. *Mediterranean Journal of Hematology and Infectious Disease*. doi: 10.4084/MJHID.2012.048
- Rojas-Peña, M. L., Vallejo, A., Herrera, S., Gibson, G., Herrera, M.A. 2015. Transcription profiling of malaria-naïve and semi-immune Colombian volunteers in a *P. vivax* sporozoite challenge. *PLoS Neglected Tropical Diseases*, 9(8), pp. 1–18. doi: 10.1371/journal.pntd.0003978.
- Rolling, T., Wichmann, D., Schmiedel, S., Burchard, G.D., Kluge, S., Cramer, J.P. 2013. Artesunate versus quinine in the treatment of severe imported malaria: Comparative analysis of adverse events focussing on delayed haemolysis. *Malaria Journal*. Malaria Journal, 12(1), p. 1. doi: 10.1186/1475-2875-12-241.
- Rowe, A., Obeiro, J., Newbold, C.I., & Marsh, K. 1995. *P. falciparum* rosetting is associated with malaria severity in Kenya. *Infection and Immunity*, 63(6), pp.

2323–2326.

- Safeukui-Noubissi, I., Ranque, S., Poudiougou, B., Keita, M., Traoré, A., Traoré, D., *et al.* 2004. Risk factors for severe malaria in Bamako, Mali: A matched case-control study. *Microbes and Infection*, 6(6), pp. 572–578. doi: 10.1016/j.micinf.2004.02.007.
- Sitohang, V., Sariwati, E., Fajariyani, S.B., Hwang, D., Kurnia, B., Hapsari, R.K., Laihad, F.J., Sumiwi, M.E., Pronyk, P., Hawley, W.A. 2018. Malaria elimination in Indonesia: halfway there. *The Lancet Global Health*. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license, 6(6), pp. e604–e606. doi: 10.1016/S2214-109X(18)30198-0.
- Smith, K.F., Goldberg, M., Rosenthal, S., Carlson, L., Chen, J., Chen, C., Ramachandran S. 2014. Global rise in human infectious disease outbreaks. *Journal of The Royal Society*. Brown University : Department of Ecology and Evolutionary Biology. USA.
- Snow, R. W., Omumbo, J.A., Lowe, B., Molyneux, C.S., Obiero, J.O., Palmer, A., *et al.* 1997. Relation between severe malaria morbidity in children and level of *P. falciparum*. 349, pp. 1650–1654.
- South African National Department of Health (2009) ‘Guidelines for the Treatment of Malaria in South Africa’, *Drugs*, p. 194. Available at: <http://www.doh.gov.za/docs/factsheets/guidelines/malaria/treat-malaria02.html>.
- Phuong, C.X.T., Bethell, D.B., Phuon, P.T., Mail, T.T.T., Thuyl, T.T.N., Hal, N.T.T., *et al.* 1997. Comparison intravenous of artemisinin suppositories , intramuscular artesunate quinine for the treatment of severe childhood malaria . *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 44, pp. 335–342.
- Teh, R.N., Sumbele, I.U.N., Meduke, D.N., Ojong, S.T., Kimbi, H. K. 2018. Malaria parasitaemia, anaemia and malnutrition in children less than 15 years residing in different altitudes along the slope of Mount Cameroon: prevalence, intensity and risk factors. *Malaria Journal*. BioMed Central, 17(1), pp. 1–13. doi: 10.1186/s12936-018-2492-1.
- Trampuz, A., Jereb, M., Muzlovic, I., Prabhu, R.M. 2003. Clinical review: Severe malaria. *Critical Care*, 7(4), pp. 315–323. doi: 10.1186/cc2183.
- Tyne, D.V., Park, D.J., Schaffner, S.F., Neafsey, D.E., Angelino, A., Cortese, J.F. 2011. Identification and Functional Validation of the Novel Antimalarial Resistance Locus *PF10_0355* in *P. Falciparum*. *PLoS Genetics*. 7(4): e1001383.

- Velip, A. P., Kulkarni, M.S, Motghare, D.D., Vaz, F.S. 2006. Determinants of hospital stay among malaria patients at a Tertiary Care Hospital in Goa. *Journal of Communicable Diseases*, 38(1), pp. 115–117.
- Verhoef, H., West, C.E., Kraaijenhagen, R., Nzyuko, S.M., King, R., Mbandi, M.M., *et al.* 2002. Malarial anemia leads to adequately increased erythropoiesis in asymptomatic Kenyan children. *Blood*, 100(10), pp. 3489–3494. doi: 10.1182/blood-2001-12-0228.
- Visser, B. J., Wieten, R.W., Kroon., Nagel, I.M., B  lard, S., Vugt., Grobusch, M.P. 2014. Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: A systematic review. *Malaria Journal*. doi: 10.1186/1475-2875-13-463.
- White, N.J. 2004. Antimalarial drug resistance. *The Journal of Clinical Investigation*. doi: 10.1172/JCI200421682.
- White, N. J. 2017. Malaria parasite clearance. *Malaria Journal*. doi: 10.1186/s12936-017-1731-1.
- WHO. 2003. The behavioural and social aspects of malaria and its control. The behavioural and social aspects of malaria and its control. United States of America : New York.
- WHO. 2010. Guidelines for The Treatment of Malaria. *ed*: 2nd. Geneva: Switzerland.
- WHO. 2015. Guideline for the treatment of malaria. *ed* : 3rd. Geneva : Switzerland.
- WHO. 2017. World Malaria Report 2017. *World Health Organization*. doi: 10.1071/EC12504.
- WHO. 2018. World Malaria Report 2018. World Health Organization.
- Zwang, J., Ashley, E.A., Karema, C., D’Alessandro, U., Smithuis, F., Dorsey, G., *et al.* 2009. Safety and Efficacy of Dihydroartemisinin-Piperaquine in Falciparum Malaria: A Prospective Multi-Centre Individual Patient Data Analysis. *PLoS ONE* 4(7): e6358. doi:10.1371/journal.pone.0006358

